Previous 10 | Next 10 |
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company launched a service platform for their first autologous product called Patient Pure X TM (PPX ...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that the Company will be presenting at the annual meeting of the International Society of Cell and Gene Therapy (ISC...
Organicell Regenerative Medicine (BPSR) has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin to hospitals and clinics in the country.Under the agreement, Apex Services will exclusively market, promote and distribute Zofin in conne...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin ...
Clinical Trials To Commence Immediately Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced its Zofin™ therapy has been approved by Pakistani reg...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it is currently exploring options to up-list its common stock to the NASDAQ Capital Market tier of the NASDAQ S...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is bein...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the company has completed enrollment for its U.S. Food and Drug Administration (FDA) granted expanded access tr...
Organicell Regenerative Medicine (BPSR) announces that the U.S. FDA has approved the Investigational New Drug ((IND)) application for its lead product, Zofin, in the treatment of knee osteoarthritis.The approved trial design, which will begin in Q2 of this year, will be a double blinded, plac...
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its...
News, Short Squeeze, Breakout and More Instantly...
Organicell Regenerative Medicine Inc Company Name:
BPSR Stock Symbol:
OTCMKTS Market:
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 7, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB:OCEL) today ...
Leading Therapeutics Research Company Begins New Era Common Stock to trade on OTCQB under the symbol "ZEOX" commencing March 5, 2024 FORT LAUDERDALE, FL / ACCESSWIRE / March 4, 2024 / ZEO ScientifiX, Inc . (OTCQB:ZEOX) (f/k/a Organicell Regenerative Medicine, Inc. - OTCQB: OCEL) today...
FORT LAUDERDALE, FL / ACCESSWIRE / November 27, 2023 / Organicell Regenerative Medicine Inc, (OTCQB:OCEL) ("Organicell" or the "Company"), today announced that it is implementing a 1-for-200 Reverse Split of the Company's common stock (the "Reverse Split") effective as of the close of business o...